Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation: results from the LenaMain trial (NCT00891384)
Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed fo...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 October 2023
|
| In: |
Cancers
Year: 2023, Volume: 15, Issue: 21, Pages: 1-17 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers15215157 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers15215157 Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/15/21/5157 
|
| Author Notes: | Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas and Guido Kobbe |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1889091685 | ||
| 003 | DE-627 | ||
| 005 | 20240703180531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240517s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15215157 |2 doi | |
| 035 | |a (DE-627)1889091685 | ||
| 035 | |a (DE-599)KXP1889091685 | ||
| 035 | |a (OCoLC)1443678719 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Boquoi, Amelie |d 1975- |e VerfasserIn |0 (DE-588)130203130 |0 (DE-627)49436713X |0 (DE-576)298060205 |4 aut | |
| 245 | 1 | 0 | |a Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation |b results from the LenaMain trial (NCT00891384) |c Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas and Guido Kobbe |
| 264 | 1 | |c 26 October 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.05.2024 | ||
| 520 | |a Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and Methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed for longitudinal changes from baseline within the groups as well as cross-sectional scores. Results: Compliance rates were high, with 95.7% at baseline and 70% during maintenance. At study entry, scores were high for functioning and low for symptoms. During maintenance, the median global health status/quality of life (GHS/QoL) was constant, without significant differences over time (median GHS/QoL: 68 at baseline and 58 for Len high and 68 for Len low at 2 years) and between treatment arms (mean change < 2). Similarly, most functional scale domains were constant. Notably, diarrhea increased consistently for both treatment arms (baseline: −1.905 (range: −5.78-1.97); end of year 2: 16.071 (range: 5.72-26.42); p < 0.05). The subgroup analysis showed that neither disease activity, duration of treatment, nor adverse events affected the health-related quality of life (HR-QoL) or utility. Conclusion: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients’ HR-QoL. | ||
| 650 | 4 | |a domain | |
| 650 | 4 | |a dosage | |
| 650 | 4 | |a lenalidomide | |
| 650 | 4 | |a maintenance | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a quality of life | |
| 700 | 1 | |a Giagounidis, Aristoteles |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Heinsch, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rummel, Mathias J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kröger, Nicolaus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Strapatsas, Judith |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haas, Rainer |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobbe, Guido |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d Basel : MDPI, 2009 |g 15(2023), 21, Artikel-ID 5157, Seite 1-17 |h Online-Ressource |w (DE-627)614095670 |w (DE-600)2527080-1 |w (DE-576)313958548 |x 2072-6694 |7 nnas |a Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation results from the LenaMain trial (NCT00891384) |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:21 |g elocationid:5157 |g pages:1-17 |g extent:17 |a Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation results from the LenaMain trial (NCT00891384) |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers15215157 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/15/21/5157 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240517 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |d 50000 |e 910000PM1049182545 |e 910100PM1049182545 |e 50000PM1049182545 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 7 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1889091685 |e 4524841636 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Amelie Boquoi, Aristoteles Giagounidis, Hartmut Goldschmidt, Michael Heinsch, Mathias J. Rummel, Nicolaus Kröger, Elias K. Mai, Judith Strapatsas, Rainer Haas and Guido Kobbe"]},"person":[{"given":"Amelie","role":"aut","display":"Boquoi, Amelie","family":"Boquoi"},{"family":"Giagounidis","display":"Giagounidis, Aristoteles","role":"aut","given":"Aristoteles"},{"family":"Goldschmidt","role":"aut","given":"Hartmut","display":"Goldschmidt, Hartmut"},{"family":"Heinsch","role":"aut","given":"Michael","display":"Heinsch, Michael"},{"display":"Rummel, Mathias J.","role":"aut","given":"Mathias J.","family":"Rummel"},{"family":"Kröger","display":"Kröger, Nicolaus","given":"Nicolaus","role":"aut"},{"display":"Mai, Elias K.","given":"Elias K.","role":"aut","family":"Mai"},{"family":"Strapatsas","display":"Strapatsas, Judith","role":"aut","given":"Judith"},{"role":"aut","given":"Rainer","display":"Haas, Rainer","family":"Haas"},{"family":"Kobbe","display":"Kobbe, Guido","given":"Guido","role":"aut"}],"origin":[{"dateIssuedDisp":"26 October 2023","dateIssuedKey":"2023"}],"recId":"1889091685","type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1889091685"],"doi":["10.3390/cancers15215157"]},"physDesc":[{"noteIll":"Illustrationen","extent":"17 S."}],"note":["Gesehen am 17.05.2024"],"relHost":[{"note":["Gesehen am 27.05.2020"],"disp":"Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation results from the LenaMain trial (NCT00891384)Cancers","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"recId":"614095670","origin":[{"publisherPlace":"Basel","publisher":"MDPI","dateIssuedDisp":"2009-","dateIssuedKey":"2009"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"pubHistory":["1.2009 -"],"part":{"text":"15(2023), 21, Artikel-ID 5157, Seite 1-17","year":"2023","volume":"15","issue":"21","extent":"17","pages":"1-17"},"language":["eng"],"title":[{"title":"Cancers","title_sort":"Cancers"}]}],"title":[{"subtitle":"results from the LenaMain trial (NCT00891384)","title":"Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation","title_sort":"Health-related quality of life in multiple myeloma patients treated with high- or low-dose lenalidomide maintenance therapy after autologous stem cell transplantation"}],"language":["eng"]} | ||
| SRT | |a BOQUOIAMELHEALTHRELA2620 | ||